Mizuno, Ryuichi

National Health Service · Brigham and Women's Hospital · Harvard University · Queen Mary University of London · Keio University · The Royal Free Hospital · Cancer Research UK · Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center · Barts Cancer Institute

2 papers on CoChatORCID 0000-0002-1507-1421

Most cited papers

Verified
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., et al. (2021) · New England Journal of Medicine
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 1,791
Verified
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology
Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers
Cited by 643

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free